⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ABBV News
ABBVIE INC.
A $190 Billion Weight-Loss Boom Exposed a Tissue-Restoration Gap, and One Nasdaq Company Is Moving to Fill It
prnewswire.com
NVO
ABBV
CNXU
LLY
Form 8-K
sec.gov
ABBV
AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
prnewswire.com
ABBV
AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
prnewswire.com
ABBV
Global Cancer Biologics Market Poised to Reach USD 189 Billion by 2035 with a CAGR of 8.9%
globenewswire.com
ABT
ABBV
AMGN
AZN
BNTX
BMY
LLY
GILD
JNJ
MRK
NVS
PFE
SNY
TAK
Non-Small Cell Lung Cancer Market Poised for Robust Expansion at a 6.6% CAGR Through 2036, Driven by Emerging Targeted and Immunotherapy Innovations | DelveInsight
prnewswire.com
PFE
ABBV
RMD
GSK
AZN
BNTX
INCY
IOVA
RGEN
MRK
LLY
IBIO
GILD
AMGN
JNJ
NVS
RIGL
BIIB
Blood Cancer United Welcomes New Board Members & Philanthropy Leadership
prnewswire.com
VVV
BIIB
BMY
GILD
MRK
PFE
AMGN
REGN
JNJ
ABBV
LULU
CGC
CRON
ACB
TLRY
SNDL
CVS
UNH
CI
CNC
HCA
THC
AI
NVDA
MSFT
GOOG
IBM
ORCL
AMD
INTC
QCOM
AMAT
MU
SMCI
ADSK
CBRE
JLL
SPG
PLD
EQIX
AMT
A Nasdaq-Listed Regenerative Tissue Company Just Opened a Lab: The Next Step in Scaling a Platform Built for a NEW Aesthetics Opportunity
globenewswire.com
CNXU
ABBV
LLY
ESTA
DigiCert Introduces Quantum Central to Help Organizations Prepare for Post-Quantum Cryptography
globenewswire.com
MSFT
GOOG
AMZN
IBM
ORCL
CSCO
NVDA
INTC
AMD
QCOM
AMAT
MU
ADBE
CRM
ACN
T
VZ
CMCSA
NFLX
DIS
BA
GD
LMT
RTX
HON
GE
CAT
JPM
BAC
WFC
C
GS
MS
AXP
V
MA
PYPL
KO
PEP
MCD
SBUX
COST
WMT
HD
UNH
JNJ
PFE
MRK
ABBV
BMY
LLY
GILD
AMGN
BIIB
REGN
VRTX
GNTX
CTAS
PAYX
ADP
LRCX
KLAC
NXPI
MRVL
SNPS
CDNS
MCHP
ON
ADI
TXN
QGEN
ILMN
MDT
SYK
ISRG
ALGN
EW
TMO
DHR
GOOGL
AAPL
META
TSLA
AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
prnewswire.com
ABBV